



## I AM ALS Patient-Centric Trial Design (PaCTD) Rating for Biogen's BIIB067

| I AM ALS Patient Centric Trial Design (PaCTD)  | Biogen<br>BIIB067 (SOD1) <sup>1</sup>              |              |
|--|--|--------------|
| Open Label Extension   | Yes  | 1            |
| Minimize placebo usage - 33% or less   | Yes (33%)  | 1            |
| A side by side Expanded Access Program   | No   | 0            |
| <b>Part 1 Total</b>  |  | <b>2</b>     |
| <b>Part 1 Rating-Seats at the Table</b>  |  | <b>0.4</b>   |
| Consideration of disease heterogeneity: e.g.,<br>Cross-Over design or Delayed Start Design   | SOD1   | 1            |
| Use of scientifically supportable inclusion criteria,<br>pre-defined subset analysis, re-randomization at<br>trial conclusion to equalize outlier progressors<br>between trial arms, or alternative controls<br>(historical, algorithmic etc.) |  | 1            |
| Investigation of biomarker   | Yes  | 1            |
| Independent Unblinded Review Panel that can<br>communicate with FDA where substantial proof of<br>“efficacy” emerges before end of trial   | No   | 0            |
| <b>Part 2 Total</b>  |  | <b>3</b>     |
| <b>Part 2 Rating-Advancing Science Quickly</b>   |  | <b>0.225</b> |
| Use of Run-In Observation Period - 3 months not<br>acceptable -1 month ideally   | No   | 1            |
| Use of novel methods: wearables, telemedicine<br>visits, financial burden  | telemedicine visits, state<br>travel reimbursement | 1            |
| <b>Part 3 Total</b>  |  | <b>2</b>     |
| <b>Part 3 Rating-Patient-Friendly</b>  |  | <b>0.1</b>   |
| <b>Total Rating</b>  |  | <b>0.725</b> |

<sup>1</sup> Biogen's clinical trial design was created before the FDA updated its ALS clinical trial guidance in the [Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry](#) in September 2019.

|                                      |  |               |
|--------------------------------------|--|---------------|
| <b>x5</b>                            |  | <b>3.625</b>  |
| <b>I AM ALS PaCTD 5-Star Rating:</b> |  | <b>4-Star</b> |